Oncolytic vaccinia virus: a silver bullet?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Dissecting residual disease in spheroids reveals pan-cancer persistence signatures and a therapeutic window for oncolytic viruses.Molecular therapy. Oncology · 2026
   Article
2. The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies.Biomedicines · 2017
   Review
3. Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes.OncoTargets and therapy · 2017
   Article
4. Oncolytic viruses: From bench to bedside with a focus on safety.Human vaccines & immunotherapeutics · 2015
   Review
5. Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy.Therapeutic delivery · 2015
   Review
6. Oncolytic Poxviruses.Annual review of virology · 2014
   Article
7. Oncolytic myxoma virus: the path to clinic.Vaccine · 2013
   Review
8. Myxoma and vaccinia viruses bind differentially to human leukocytes.Journal of virology · 2013
   Article
9. Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition.Oncoimmunology
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as